ArticleBMC nutrition2026
Effects of multistrain probiotics on metabolic biomarkers, inflammation, and antioxidant system in patients with type 2 diabetes mellitus: a prospective controlled trial in Türkiye.
Article in BMC nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07330388 (The Effects of Probiotics on Metabolic Biomarkers, Inflammation, and the Antioxidant System in Patients With Type 2 Diabetes Mellitus), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Probiotics on Metabolic Biomarkers, Inflammation, and the Antioxidant System in Patients With Type 2 Diabetes Mellitus
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRecent evidence suggests that the gut microbiota plays a crucial role in the development and progression type 2 diabetes mellitus (T2DM). This study aimed to investigate the effects of multi-strain probiotic supplementation on glucose and lipid metabolism, inflammation, and antioxidant system in patients with T2DM.
methodsThis prospective controlled clinical trial was conducted at Ege University Faculty of Medicine from July 2020 to June 2023. Participants aged 35-65 years diagnosed with T2DM were allocated sequentially according to order of presentation to either probiotic group (n = 39) or control group (n = 38). The intervention group received a multi-strain probiotic supplement containing Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium lactis and Lactobacillus paracasei, twice daily for 12 weeks, while the control group continued standard care. This study evaluated anthropometric measurements, eating attitudes, dietary frequency, quality of life, and physical activity. Biochemical analyses included glycemic control, lipid profiles, inflammation markers (high-sensitivity C-Reactive Protein, Ceruloplasmin), and oxidative stress markers (Malondialdehyde, Glutathione).
resultsSeventy-seven of the 80 participants completed the study (mean age 55.38 ± 6.40 years, 42.86% female). After 12 weeks a significant within-group decrease in fasting blood glucose (FBG), postprandial blood glucose (PPBG), HbA1c, LDL-C, Non-HDL-C and malondialdehyde in the probiotic group compared to the control group (p < 0.001, p = 0.003, p = 0.004, p = 0.044, p = 0.034, p = 0.001). No significant changes were observed in inflammatory markers or oxidative stress markers' levels. Anthropometric parameters remained unchanged in both groups. In a two-group comparison, three-month multi-strain probiotic supplementation statistically significantly improved only PPBG in patients with T2DM (p = 0.038).
conclusionsThree months of multi-strain probiotic supplementation led to a significant reduction in PPBG levels among patients with T2DM, while FBG, HbA1c, lipid profile parameters, and inflammatory and oxidative stress markers showed improvements that did not reach statistical significance. CLINICAL
trial registrationClinialTrials.gov registration number: NCT07330388. Registered on 23 December 2025. https://clinicaltrials.gov/search?term=NCT07330388.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.